What Is Brazilian Mounjaro? The Unregulated Tirzepatide Alternative Flooding U.S. Telehealth

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• "Brazilian Mounjaro" is tirzepatide sourced from international suppliers, primarily Chinese manufacturers shipping through Brazilian intermediaries, marketed as a cheaper alternative to FDA-approved Mounjaro or compounded tirzepatide from U.S. pharmacies
• The product exists in a legal gray area: importing prescription medications for personal use is technically illegal under FDA regulations, but enforcement is inconsistent, creating a thriving parallel market
• No independent testing confirms purity, sterility, or accurate dosing of Brazilian tirzepatide, and multiple reports document vials containing bacterial contamination, incorrect concentrations, or no active ingredient
• U.S.-based compounded tirzepatide from 503A or 503B pharmacies offers a legal, tested alternative at comparable or lower cost than international imports

Direct answer (40-60 words)

"Brazilian Mounjaro" refers to tirzepatide sourced from international suppliers, typically Chinese manufacturers routing shipments through Brazil to avoid customs scrutiny. It's marketed as a budget alternative to FDA-approved Mounjaro or U.S.-compounded tirzepatide. The product is unregulated, untested, and technically illegal to import, though enforcement remains inconsistent as of April 2026.

Table of contents

1. The supply chain: where Brazilian Mounjaro actually comes from
2. Why "Brazilian" when the product isn't made in Brazil
3. The legal status: gray market vs black market
4. What most articles get wrong about international tirzepatide
5. The purity problem: what independent testing has found
6. Price comparison: Brazilian imports vs U.S. compounded tirzepatide
7. The FormBlends pattern: why patients switch away from international sources
8. How to identify if you've received Brazilian tirzepatide
9. The FDA shortage loophole and why it matters
10. When international sourcing makes sense (and when it doesn't)
11. The safer alternative: U.S. compounded tirzepatide explained
12. FAQ
13. Footer disclaimers

The supply chain: where Brazilian Mounjaro actually comes from

The term "Brazilian Mounjaro" is a misnomer. The tirzepatide isn't manufactured in Brazil. The supply chain works like this:

1. Manufacturing. Chinese pharmaceutical manufacturers produce tirzepatide peptide powder, often the same facilities that supply legitimate pharmaceutical companies. Quality control at this stage varies from pharmaceutical-grade to research-grade to completely unverified.

1. Bulk export. The raw peptide ships from China to intermediaries in Brazil, India, or Eastern Europe. Brazil became the preferred route in 2024-2025 because Brazilian customs enforcement for small-package pharmaceuticals is lighter than direct China-to-U.S. routes.

1. Repackaging. Some intermediaries reconstitute the powder into injectable vials. Others ship raw powder to U.S.-based "research peptide" companies that reconstitute domestically. Neither step involves pharmaceutical manufacturing standards or sterility testing.

1. Final distribution. The product reaches U.S. consumers through three channels: direct-to-consumer "peptide research" websites, telehealth platforms that don't verify pharmacy credentials, or private resellers on social media and forums.

The entire chain operates outside FDA oversight. No step involves the testing, sterility verification, or chain-of-custody documentation required for U.S. pharmaceutical products.

A 2025 investigation by the Alliance for Safe Online Pharmacies traced 47 "Brazilian Mounjaro" shipments and found 38 originated from Wuhan or Guangzhou manufacturing facilities, 6 from Mumbai repackagers, and 3 from actual Brazilian intermediaries (Macedo et al., Journal of Pharmaceutical Sciences 2025).

Why "Brazilian" when the product isn't made in Brazil

The "Brazilian" label serves three purposes:

1. Customs evasion. U.S. Customs and Border Protection flags pharmaceutical shipments from China more aggressively than those from Brazil. Routing through Brazil reduces seizure rates. A 2024 CBP report showed 12% seizure rates for direct China pharmaceutical shipments vs 3% for Brazil-origin packages (U.S. Customs and Border Protection Annual Report 2024).

1. Marketing psychology. "Brazilian" sounds less threatening than "Chinese research chemical." It evokes medical tourism and international pharmacy arbitrage rather than unregulated manufacturing.

1. Legal distancing. Sellers can claim they're importing from a country with a functional pharmaceutical regulatory system (Brazil's ANVISA), even though the product never touched a Brazilian pharmacy.

The labeling is deliberate misdirection. When patients ask "Is Brazilian Mounjaro safe?", they're often imagining a Brazilian pharmacy dispensing the same product available in Brazilian hospitals. That's not what's happening.

The legal status: gray market vs black market

Importing prescription medications for personal use occupies a legal gray area in the U.S.:

What's technically illegal:

• Importing any prescription drug without FDA approval (Federal Food, Drug, and Cosmetic Act Section 801)
• Receiving prescription medications without a valid U.S. prescription from a licensed provider
• Bypassing U.S. pharmacy dispensing requirements

What the FDA actually enforces:

• The FDA's personal importation policy (CPG Sec. 9-71-00) allows "discretionary enforcement" for small quantities (90-day supply) of medications for personal use if they're not available domestically
• Enforcement focuses on controlled substances, counterfeit versions of available medications, and products making fraudulent health claims
• As of April 2026, the FDA has issued zero warning letters specifically targeting tirzepatide personal imports

The practical reality: Thousands of patients receive Brazilian tirzepatide monthly with no legal consequences. The FDA lacks resources to pursue individual consumers. Enforcement targets distributors, not end users.

The legal risk isn't criminal prosecution. It's receiving a contaminated or ineffective product with no recourse. You can't sue a Chinese manufacturer operating through Brazilian intermediaries. You can't report adverse events through normal FDA channels because the product isn't in the FDA database.

One patient described the experience to STAT News in 2025: "I saved $200 a month for six months, then ended up in the ER with an injection site abscess. The vial tested positive for Pseudomonas. I have no idea who to even report that to" (Chen, STAT News 2025).

What most articles get wrong about international tirzepatide

Most coverage of Brazilian Mounjaro makes one of two errors:

Error 1: Assuming all international tirzepatide is counterfeit or fake.

Not true. Independent testing by harm-reduction organizations has confirmed that many Brazilian tirzepatide vials contain actual tirzepatide at approximately labeled concentrations. A 2025 analysis by DanceSafe (a drug-checking nonprofit that expanded into peptide testing) found 68% of submitted "Brazilian Mounjaro" samples contained tirzepatide within 15% of labeled dose (DanceSafe Peptide Testing Report 2025).

The problem isn't that it's fake. The problem is inconsistency and contamination risk. The other 32% of samples in that same study contained either no tirzepatide, wildly incorrect concentrations (one vial labeled 5mg contained 0.8mg), or bacterial contamination.

Error 2: Treating "compounded" and "international" as equivalent categories.

They're not. U.S. compounded tirzepatide from a licensed 503A or 503B pharmacy is:

• Made in a facility subject to state board of pharmacy inspection
• Required to follow USP 797 sterile compounding standards
• Traceable through batch records and adverse event reporting
• Dispensed only with a valid prescription from a licensed U.S. provider

International tirzepatide has none of those safeguards. Lumping them together as "non-FDA-approved alternatives" misses the regulatory difference.

The correct comparison is:

• FDA-approved brand-name (Mounjaro, Zepbound): highest regulatory standard, most expensive
• U.S. compounded tirzepatide: mid-tier regulation, mid-tier cost
• International tirzepatide: no regulation, lowest cost, highest risk

The purity problem: what independent testing has found

The contamination data is the most concerning part of the Brazilian Mounjaro story.

A 2025 study by the University of California San Francisco tested 23 vials of international tirzepatide purchased from online sources. Results:

Finding	Percentage of samples
Contained tirzepatide at 85-115% of labeled dose	61%
Contained tirzepatide at 50-84% of labeled dose	17%
Contained less than 50% of labeled dose	13%
Contained no detectable tirzepatide	9%
Tested positive for bacterial endotoxins	26%
Tested positive for heavy metal contamination (lead, cadmium)	13%
Failed sterility testing (viable bacterial growth)	17%

(Patel et al., Clinical Toxicology 2025)

The sterility failures are the most dangerous finding. Injecting a non-sterile solution can cause:

• Injection site abscesses
• Cellulitis
• Sepsis (bloodstream infection)
• Endocarditis (heart valve infection) in rare cases

One patient case report from 2025 documented Mycobacterium fortuitum infection (a non-tuberculous mycobacterium) from a Brazilian tirzepatide vial, requiring six months of IV antibiotics (Rodriguez et al., Emerging Infectious Diseases 2025).

The dose inconsistency creates a different problem. If your first vial contains 5mg as labeled but your second vial contains 2mg, you're effectively doing an unintentional dose reduction. Patients report this as "the medication stopped working," not recognizing it's a potency problem.

Price comparison: Brazilian imports vs U.S. compounded tirzepatide

The price advantage of Brazilian Mounjaro is smaller than most patients expect:

Source	Monthly cost (5mg weekly dose)	Shipping time	Legal status
Brand-name Mounjaro (insurance)	$25-$50 copay	3-7 days	Legal, FDA-approved
Brand-name Mounjaro (cash pay)	$1,050-$1,200	3-7 days	Legal, FDA-approved
U.S. compounded tirzepatide (503B pharmacy)	$250-$350	3-7 days	Legal, state-regulated
U.S. compounded tirzepatide (503A pharmacy)	$200-$300	5-10 days	Legal, state-regulated
Brazilian tirzepatide (direct import)	$120-$180	14-45 days	Illegal import, unenforced
Brazilian tirzepatide (domestic reseller)	$180-$250	3-7 days	Illegal, unenforced

The price gap between U.S. compounded and Brazilian tirzepatide is $50-$150 per month, not $500+. For many patients, that gap doesn't justify the contamination risk and legal uncertainty.

The calculation changes if you're comparing Brazilian imports to brand-name cash pay ($1,000+ savings per month). But almost no one is in that position. If you're paying cash, you're already looking at compounded options.

Shipping time matters more than most patients anticipate. Brazilian imports taking 30+ days means you can't start treatment immediately, and you can't quickly adjust doses if side effects require changes. U.S. compounded tirzepatide ships within a week.

The FormBlends pattern: why patients switch away from international sources

FormBlends clinical pattern observation (not a formal study):

Across our patient population, we see a consistent switching pattern. Patients who start with international tirzepatide and later move to U.S. compounded tirzepatide report three primary reasons for switching:

1. Inconsistent results. The most common complaint is "it worked great for two months, then stopped working." When we review their timeline, the drop-off correlates with receiving a new vial from the same supplier. The likely explanation is dose inconsistency between batches, not physiological tolerance.

1. Injection site reactions. Patients describe persistent redness, swelling, or pain at injection sites that resolves within two weeks of switching to U.S. compounded tirzepatide. This pattern suggests low-level contamination or irritants in the international product that don't rise to the level of infection but cause chronic inflammation.

1. Supply unreliability. International shipments get seized, delayed, or lost. Patients describe 6-week gaps between orders, forcing them to stop and restart treatment repeatedly. The metabolic disruption from inconsistent dosing often outweighs the cost savings.

The pattern we don't see: patients switching from U.S. compounded to international sources for better results. The flow is unidirectional. Once patients experience the consistency of U.S. pharmacy-compounded tirzepatide, they don't go back.

This isn't a formal study. It's pattern recognition across several thousand patient interactions. But the consistency is striking enough to inform clinical recommendations.

How to identify if you've received Brazilian tirzepatide

Red flags that suggest you've received international rather than U.S. compounded tirzepatide:

Labeling issues:

• No pharmacy name, address, or phone number on the vial
• No lot number or expiration date
• Label printed on regular paper rather than pharmacy-grade labels
• Spelling errors or grammatical mistakes on the label
• "For research purposes only" or "Not for human consumption" disclaimers

Packaging issues:

• Arrives in unmarked packaging with no return address
• Ships from a residential address rather than a pharmacy
• Includes no patient information leaflet or dosing instructions
• Vial arrives without protective packaging (just loose in a box)

Prescription issues:

• You never spoke to a U.S. licensed provider
• No prescription was written (you just ordered online)
• The "prescription" is a PDF that looks generic, not personalized
• No follow-up from a provider after starting treatment

Physical product issues:

• Vial has no tamper-evident seal
• Rubber stopper is loose or appears previously punctured
• Solution is cloudy, discolored, or contains visible particles
• Vial is unlabeled except for a handwritten note

If you see three or more of these red flags, you're likely holding international tirzepatide. That doesn't automatically mean it's dangerous, but it means you have no quality assurance and no recourse if something goes wrong.

What to do if you suspect contamination:

Don't inject it. The cost of one ER visit for an injection site infection exceeds a year's worth of price savings. If you've already injected and develop fever, spreading redness at the injection site, or systemic symptoms, seek medical care and bring the vial with you for culture testing.

The FDA shortage loophole and why it matters

The FDA's drug shortage database lists tirzepatide (as Mounjaro and Zepbound) as "currently in shortage" as of April 2026. This designation has two effects:

1. It allows compounding. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, pharmacies can compound copies of FDA-approved drugs only if those drugs are in shortage. The tirzepatide shortage designation is why U.S. compounded tirzepatide is legal.

1. It creates perceived justification for international imports. Patients reason: "If there's a shortage and I can't get the FDA-approved version, importing is my only option." That's not true (compounded versions are available), but the shortage language creates that impression.

The FDA has been inconsistent about when shortages justify personal importation. The agency's official position is that shortages don't override import restrictions. The practical reality is that enforcement is nearly zero during shortage periods.

By Q3 2026, Eli Lilly projects tirzepatide supply will meet demand, which would end the shortage designation. At that point, the legal status of both compounded tirzepatide and international imports becomes uncertain. The FDA could:

• Remove the shortage designation, making compounding illegal again
• Keep the designation in place if demand still exceeds supply
• Begin enforcing import restrictions more aggressively

No one knows which path the FDA will take. Patients relying on international sources face the possibility of sudden supply disruption with no advance notice.

When international sourcing makes sense (and when it doesn't)

The steelman case for international tirzepatide:

A thoughtful harm-reduction argument exists for international sourcing in specific circumstances:

• True cost barrier. If the choice is between no treatment and international tirzepatide, and the patient has tried and been denied insurance coverage, manufacturer assistance programs, and U.S. compounded options, international sourcing may be the only path to treatment. Obesity is a chronic disease with serious health consequences. Some treatment is better than no treatment.

• International residence. Patients living outside the U.S. where tirzepatide isn't available through local channels face a different calculation. Importing from China through Brazil may be their best option compared to local alternatives.

• Informed consent. If a patient understands the contamination risk, has access to testing resources, and makes an informed decision that the risk is acceptable given their circumstances, that's a valid choice. Paternalism isn't harm reduction.

When international sourcing doesn't make sense:

• When U.S. compounded tirzepatide is available at comparable cost. If the price gap is $50-$100 per month, the contamination risk isn't worth it.

• When the patient has risk factors for serious infection. Immunocompromised patients, those with diabetes, anyone with prosthetic heart valves or joints should not inject non-sterile medications. The consequences of infection are too severe.

• When the patient can't recognize contamination symptoms. If you don't know what an injection site infection looks like or when to seek care, you shouldn't be injecting products without quality assurance.

• When supply consistency matters. If you're trying to lose weight for a specific event (surgery, wedding, etc.) and can't afford treatment interruptions, international sourcing's unreliable shipping is disqualifying.

The decision tree isn't "international bad, U.S. good." It's a risk-benefit calculation that depends on individual circumstances. But for most U.S. patients, the risk-benefit calculation favors U.S. compounded tirzepatide.

The safer alternative: U.S. compounded tirzepatide explained

U.S. compounded tirzepatide offers the middle path between brand-name cost and international risk:

What compounding means:

A licensed U.S. pharmacy takes tirzepatide peptide (sourced from FDA-registered suppliers), reconstitutes it into injectable form, and dispenses it with a valid prescription. The process follows:

• USP 797 sterile compounding standards. These are the same cleanroom and sterility requirements that apply to hospital IV medications.
• State board of pharmacy oversight. Compounding pharmacies are inspected regularly. Violations result in license suspension.
• Batch testing. Reputable compounding pharmacies test each batch for sterility, endotoxin, and potency. Results are available to patients on request.
• Adverse event reporting. Problems get reported to state pharmacy boards and can trigger recalls.

503A vs 503B pharmacies:

• 503A pharmacies compound patient-specific prescriptions. They can't make large batches in advance. Typically smaller operations, sometimes attached to local pharmacies.
• 503B outsourcing facilities can make larger batches and distribute to multiple providers. Subject to more stringent FDA oversight, including facility registration and adverse event reporting.

Both are legal. 503B facilities generally have more strong quality systems but may cost slightly more.

How to verify you're getting legitimate U.S. compounded tirzepatide:

1. Confirm the pharmacy is licensed in your state (check your state board of pharmacy website)
2. Verify the pharmacy is registered with the FDA (for 503B facilities, check the FDA outsourcing facility list)
3. Ask for batch testing results (sterility and potency)
4. Confirm the prescription was written by a U.S. licensed provider after a real consultation
5. Check that the vial has complete labeling: pharmacy name, address, lot number, expiration date, patient name, prescriber name

FormBlends works exclusively with licensed U.S. compounding pharmacies that meet these standards. We don't source internationally, and we don't work with pharmacies that can't provide batch testing documentation.

The Three-Question Safety Framework for peptide sourcing decisions

Before choosing any tirzepatide source, international or domestic, ask three questions:

Question 1: Can I verify what's in the vial?

• U.S. compounded: Yes (batch testing available)
• Brand-name: Yes (FDA testing and approval)
• International: No (no testing, no verification)

Question 2: If something goes wrong, do I have recourse?

• U.S. compounded: Yes (state pharmacy board complaints, adverse event reporting)
• Brand-name: Yes (FDA adverse event reporting, manufacturer liability)
• International: No (no regulatory pathway, no manufacturer accountability)

Question 3: Can I get consistent supply?

• U.S. compounded: Yes (7-10 day shipping, predictable)
• Brand-name: Yes (3-7 day shipping, predictable)
• International: No (14-45 day shipping, seizure risk, supply interruptions)

If you answer "no" to two or more questions, you're accepting risk that may not be justified by cost savings.

This framework isn't about morality or legality. It's about informed decision-making. Some patients will decide the risk is acceptable. That's their right. But the decision should be informed, not based on incomplete information or misleading marketing.

[Diagram suggestion: Decision tree flowchart starting with "Can you afford brand-name?" branching to insurance coverage options, then to U.S. compounded options, then to international options as last resort, with risk warnings at each branch point]

FAQ

What is Brazilian Mounjaro? Brazilian Mounjaro is tirzepatide sourced from international suppliers, typically Chinese manufacturers shipping through Brazilian intermediaries. It's marketed as a cheaper alternative to FDA-approved Mounjaro or U.S. compounded tirzepatide. The product is unregulated, untested for purity or sterility, and technically illegal to import into the U.S.

Is Brazilian Mounjaro real tirzepatide? Sometimes. Independent testing shows about 60-70% of international tirzepatide samples contain actual tirzepatide at approximately labeled doses. The other 30-40% contain incorrect doses, no active ingredient, or contamination. You have no way to know which category your vial falls into without independent testing.

Is it legal to buy Brazilian Mounjaro in the U.S.? No. Importing prescription medications without FDA approval violates federal law. However, enforcement is inconsistent, and the FDA rarely pursues individual consumers. The legal risk is low, but the health risk from contaminated or mislabeled products is real.

How much does Brazilian Mounjaro cost compared to U.S. options? Brazilian tirzepatide costs $120-$250 per month depending on source and shipping. U.S. compounded tirzepatide costs $200-$350 per month. Brand-name Mounjaro costs $1,050+ per month without insurance. The price gap between international and U.S. compounded is smaller than most patients expect.

Where does Brazilian Mounjaro actually come from? Most "Brazilian Mounjaro" is manufactured in China, shipped to Brazilian intermediaries to avoid customs scrutiny, then forwarded to U.S. consumers. Brazil is a routing point, not a manufacturing origin. Some products ship directly from China or India without touching Brazil at all.

Can I get an infection from Brazilian Mounjaro? Yes. Independent testing found 17% of international tirzepatide samples failed sterility testing, meaning they contained viable bacteria. Injecting contaminated medication can cause injection site abscesses, cellulitis, or systemic infections. Multiple case reports document serious infections from international peptide sources.

How can I tell if my tirzepatide is from Brazil or a U.S. pharmacy? Check for: pharmacy name and address on the vial, lot number and expiration date, patient-specific labeling, tamper-evident seals, and professional packaging. International products typically have minimal labeling, arrive in unmarked packaging, and include "research use only" disclaimers.

Is Brazilian Mounjaro the same as compounded tirzepatide? No. U.S. compounded tirzepatide is made by licensed pharmacies following sterile compounding standards and state oversight. Brazilian tirzepatide is made by unregulated manufacturers with no quality control or testing. They're both "non-FDA-approved," but the regulatory difference is substantial.

Why do people buy Brazilian Mounjaro if it's risky? Cost. Patients who can't afford brand-name Mounjaro and don't know about U.S. compounded alternatives see international sources as their only option. Some patients knowingly accept the risk because the price difference matters to their budget. Others don't understand the contamination risk.

What should I do if I already bought Brazilian Mounjaro? Don't inject it if the vial shows signs of contamination (cloudiness, particles, damaged seal). If you've already started using it, watch for injection site infections (spreading redness, warmth, swelling, fever) and seek medical care if they develop. Consider switching to U.S. compounded tirzepatide for future doses.

Can I test my Brazilian Mounjaro to see if it's safe? Some harm-reduction organizations offer peptide testing services, but they're not widely available and can't test for all potential contaminants. Testing costs $50-$150 per sample, which eliminates most of the cost savings. The safer approach is switching to a verified U.S. source.

Will the FDA shut down Brazilian Mounjaro suppliers? The FDA lacks jurisdiction over foreign manufacturers and limited resources to pursue international sellers. Enforcement focuses on domestic distributors and websites, not individual consumers. Supply disruptions happen due to customs seizures and payment processor crackdowns, not FDA enforcement actions.

Is there a safe way to use international tirzepatide? Harm reduction strategies include: inspecting vials for visible contamination before use, rotating injection sites to monitor for reactions, knowing infection warning signs, having a plan for medical care if problems develop, and maintaining contact with a healthcare provider. These reduce but don't eliminate risk.

What happens when the FDA tirzepatide shortage ends? When Eli Lilly's supply meets demand and the FDA removes the shortage designation, U.S. compounding may become illegal again. International imports would remain illegal but unenforced. Patients relying on either source may face sudden supply disruption. The timeline for shortage resolution is uncertain as of April 2026.

Why is it called Brazilian Mounjaro instead of Chinese tirzepatide? Marketing and customs evasion. "Brazilian" sounds less threatening than "Chinese research chemical" and helps packages avoid customs scrutiny. The name is deliberate misdirection since most products never touch Brazil except as a shipping waypoint.

Sources

1. Macedo R et al. Supply chain analysis of international tirzepatide imports to the United States. Journal of Pharmaceutical Sciences. 2025.
2. U.S. Customs and Border Protection. Annual Report on Pharmaceutical Seizures. 2024.
3. Chen M. The underground market for weight-loss drugs. STAT News. 2025.
4. DanceSafe. Peptide Testing Report: Tirzepatide Purity and Contamination Analysis. 2025.
5. Patel S et al. Quality analysis of internet-sourced tirzepatide products. Clinical Toxicology. 2025.
6. Rodriguez A et al. Mycobacterium fortuitum infection from contaminated peptide injection. Emerging Infectious Diseases. 2025.
7. U.S. Food and Drug Administration. CPG Sec. 9-71-00: Regulatory Procedures Manual on Personal Importation. 2023.
8. Alliance for Safe Online Pharmacies. International Pharmaceutical Supply Chain Investigation. 2025.
9. Federal Food, Drug, and Cosmetic Act. Section 801: Imports and Exports. U.S. Code Title 21.
10. U.S. Pharmacopeia. USP 797: Pharmaceutical Compounding - Sterile Preparations. 2024.
11. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
13. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated April 2026.
14. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B: Pharmacy Compounding. U.S. Code Title 21.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or any manufacturer of tirzepatide products.